BAM
Brave Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $658K | Buy |
13,534
+8,125
| +150% | +$395K | 0.18% | 65 |
|
|
2025
Q1 | $184K | Sell |
5,409
-2,150
| -28% | -$73.2K | 0.06% | 134 |
|
|
2024
Q4 | $298K | Hold |
7,559
| – | – | 0.09% | 102 |
|
|
2024
Q3 | $355K | Hold |
7,559
| – | – | 0.09% | 91 |
|
|
2024
Q2 | $408K | Sell |
7,559
-889
| -11% | -$48K | 0.1% | 82 |
|
|
2024
Q1 | $576K | Buy |
8,448
+1,393
| +20% | +$94.9K | 0.15% | 67 |
|
|
2023
Q4 | $442K | Buy |
7,055
+2,389
| +51% | +$150K | 0.12% | 76 |
|
|
2023
Q3 | $212K | Buy |
4,666
+1
| +0% | +$45 | 0.06% | 113 |
|
|
2023
Q2 | $262K | Sell |
4,665
-983
| -17% | -$55.2K | 0.08% | 101 |
|
|
2023
Q1 | $255K | Buy |
+5,648
| New | +$255K | 0.08% | 101 |
|
|
2022
Q2 | – | Sell |
-3,500
| Closed | -$220K | – | 149 |
|
|
2022
Q1 | $220K | Hold |
3,500
| – | – | 0.08% | 129 |
|
|
2021
Q4 | $265K | Buy |
3,500
+1,000
| +40% | +$75.7K | 0.07% | 115 |
|
|
2021
Q3 | $280K | Buy |
+2,500
| New | +$280K | 0.08% | 108 |
|